Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.

NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators

TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.

METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help

NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product

COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors

INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
CALC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 11, 2026
Report Source: 2026 1st Quarter Report
CalciMedica Inc. Stock Analysis CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Read More CalciMedica Inc (CALC) Chart
Key Statistics of CalciMedica Inc (CALC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.79Volume
56.76KP/E Ratio (TTM)
-52 Week Range
Market Cap
9.95MAvg. Volume
321.22KDividend Yield
-Financial Metrics & Statements of CalciMedica Inc (CALC)
FAQ's for CalciMedica Inc (CALC)
- According to Musaffa’s Shariah screening methodology, CalciMedica Inc (CALC) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CalciMedica Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in CalciMedica Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of CalciMedica Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of CalciMedica Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of CalciMedica Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.